Alpha-3-beta-2-alpha-6-containing nicotinic acetylcholine receptor (α3β2α6* nAChR)

Alpha-3-beta-2-alpha-6-containing nicotinic acetylcholine receptors (α3β2α6* nAChRs) are a specific subtype of pentameric ligand-gated ion channels predominantly expressed in the catecholaminergic nuclei of the brain, such as the substantia nigra and ventral tegmental area. These receptors are uniquely positioned on the terminals of dopaminergic neurons where they play a pivotal role in regulating the release of dopamine into the striatum (Quik et al., 2011, PMID: 21429112). Due to this localization, they are heavily implicated in the pathophysiology of Parkinson's disease, as they are among the most vulnerable receptor populations during dopaminergic cell loss (Gotti et al., 2010, PMID: 20130184). Additionally, they are key mediators of the rewarding and reinforcing properties of nicotine, making them significant targets for smoking cessation therapies (Changeux, 2010, PMID: 20383134). Pharmacological agents targeting these receptors include agonists like nicotine and varenicline, as well as highly selective research tools like alpha-conotoxins. Developing selective modulators for this subtype is a major focus in neuropharmacology to treat movement disorders and addiction while minimizing side effects associated with other nicotinic receptor subtypes found in the autonomic nervous system.

Other names

α3β2α6 nAChRAlpha6-containing nicotinic receptorsAlpha6* nAChRCHRNA6/CHRNA3/CHRNB2 complexAlpha-6-alpha-3-beta-2 nicotinic receptor

Agonist binding to the extracellular subunit interfaces induces a conformational change that opens a cation-selective pore, leading to neuronal depolarization and the release of neurotransmitters, particularly dopamine.